Iovance Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Iovance Biotherapeutics Inc's ROI in the second quarter of 2026?
Iovance Biotherapeutics Inc recorded a cumulative net loss of $-290 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -36.59%.

Within the Healthcare sector 395 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3566 to 3662.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-4.06 %	-7.17 %	-3.62 %	0.34 %	6.81 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	809	796	775	785	785
Return On Investment (TTM)	-36.59 %	-45.05 %	-48.9 %	-49.53 %	-47.28 %
IOVA's Overall Ranking	# 3662	# 3566	# 1387	# 3187	# 3244
Seq. Investment Change TTM	0.74 %	-1.76 %	-0.41 %	-2.66 %	-2.52 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-290	-354	-391	-398	-390

IOVA Company Profile >> Back to IOVA Roi Comparisons >> See Annual IOVA Return On Investment

Return On Investment IOVA's Ranking
Within:	No.
Industry	# 47
Sector	# 396
Overall	# 3662

Return On Investment Statistics
High	Average	Low
-25.27 %	-60.05 %	-373.71 %
(Dec 31 2015)		(Mar 31 2014)

Financial Statements
Iovance Biotherapeutics Inc's II. Quarter Investments	$ 809 Millions	IOVA's Balance sheet
Iovance Biotherapeutics Inc's II. Quarter Income	$ -47 Millions	Quarterly IOVA's Income Statement
IOVA's Income by Division		See IOVA's Income by Division

IOVA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	775	788	670	501	623
Y / Y Investment Growth	-1.68 %	17.62 %	33.84 %	-19.6 %	-6.82 %
Net Income in Millions	-391	-372	-444	-396	-342
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-50.46 %	-47.23 %	-66.27 %	-79.08 %	-54.97 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IOVA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IOVA's Competitors
Subscribers only: Roi for Iovance Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for IOVA's Customers

Other Ratios
IOVA's Roa	IOVA's Inventory Turnover Ratio	IOVA's Growth Rates	IOVA's Dividend Statistics
	IOVA's Profitability Ratios	IOVA's Asset Turnover Ratio	IOVA's Dividend Growth
IOVA's Roe	IOVA's Valuation Ratios	IOVA's Financial Strength Ratios	IOVA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:11:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.